Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 1, 2014, Pages 25-37

  Mikulca, J A ^a   Nguyen, V ^a   Gajdosik, D A ^a   Teklu, S G ^a   Giunta, E A ^a   Lessa, E A ^a   Tran, C H ^a   Terak, E C ^a   Raffa, R B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

amyloid; Alzheimer disease; clinical trial; preclinical Alzheimer; secretase inhibitor; therapy

Indexed keywords

ACI 91; AVAGACESTAT; BETA SECRETASE INHIBITOR; CTS 21166; DIAGNOSTIC AGENT; FLUORINE 18; GAMMA SECRETASE INHIBITOR; JNJ 40418677; LY 2811376; SEMAGACESTAT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMAGING;

ALZHEIMER DISEASE; CLINICAL TRIAL; PRECLINICAL ALZHEIMER; SECRETASE INHIBITOR; THERAPY; Β-AMYLOID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891834492     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12112     Document Type: Article

References (80)

1. Alzheimer A,. Über eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cerebral cortex]. Allgemeine Z Psychiatrie Psychisch-Gerichtliche Med, 1907; 64: 146-148.
2. Thies W, Bleiler L,. 2013 Alzheimer's disease facts and figures. Alzheimers Dement, 2013; 9: 208-245.
3. Maiorini AF, Gaunt MJ, Jacobsen TM, McKay AE, Waldman LD, Raffa RB,. Potential novel targets for Alzheimer pharmacotherapy: I secretases. J Clin Pharm Ther, 2002; 27: 169-183.
4. Callaway E,. Alzheimer's drugs take a new tack. Nature, 2012; 489: 13-14.
5. Jonsson T, Atwal JK, Steinberg S, et al,. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature, 2012; 488: 96-99.
6. Luo Y, Bolon B, Kahn S, et al,. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci, 2001; 4: 231-232.
7. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y,. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron, 1994; 13: 45-53.
8. Tomita T, Iwatsubo T,. gamma-secretase as a therapeutic target for treatment of Alzheimer's disease. Curr Pharm Des, 2006; 12: 661-670.
9. Dermaut B, Theuns J, Sleegers K, et al,. The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Am J Hum Genet, 2002; 70: 1568-1574.
10. Chen F, Hasegawa H, Schmitt-Ulms G, et al,. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature, 2006; 440: 1208-1212.
11. Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF,. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D, 2006; 7: 87-97.
12. Mullard A,. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov, 2012; 11: 657-660.
13. Landhuis E, (2012) Wave of New BACE Inhibitors Heading to Phase 2. Avialable at: http://www.alzforum.org/new/detail.asp?id=3222 (accessed 28 October 2013).
14. Wang L, Rahn JJ, Lun X, et al,. Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol, 2008; 6: e289.
15. NCT00594568. Effect of LY450139 on the Long Term Progression of Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/NCT00594568 (accessed 28 October 2013).
16. NCT00762411. Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (IDENTITY-2). Available at: http://clinicaltrials.gov/show/NCT00762411 (accessed 28 October 2013).
17. NCT00810147. A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/NCT00810147 (accessed 28 October 2013).
18. NCT01303744. Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment (CT04). Available at: http://clinicaltrials.gov/show/NCT01303744 (accessed 28 October 2013).
19. NCT00470418. Development of NIC5-15 in the Treatment of Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/NCT00470418 (accessed 28 October 2013).
20. NCT00621010. Safety Study of CTS21166 to Treat Alzheimer Disease. Available at: http://clinicaltrials.gov/show/NCT00621010 (accessed 28 October 2013).
21. NCT01294540. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort. Available at: http://clinicaltrials.gov/show/NCT01294540 (accessed 28 October 2013).
22. NCT01511783. Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects. Available at: http://clinicaltrials.gov/show/NCT01511783 (accessed 28 October 2013).
23. NCT00838084. A Safety Study of LY2811376 Single Doses in Healthy Subjects. Available at: http://clinicaltrials.gov/show/NCT00838084 (accessed 28 October 2013).
24. NCT01561430. Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/NCT01561430 (accessed 28 October 2013).
25. NCT01739348. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH). Available at: http://clinicaltrials. gov/show/NCT01739348 (accessed 28 October 2013).
26. EudraCT2008-005260-14. A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months' treatment with ACI-91 in patients with mild to moderate Alzheimer's Disease. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005260-14/AT (accessed 28 October 2013).
27. NCT00574132. Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)-Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier). Available at: http://clinicaltrials. gov/show/NCT00574132 (accessed 28 October 2013).
28. NCT00905372. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION). Available at: http://clinicaltrials.gov/show/NCT00905372 (accessed 28 October 2013).
29. NCT01760005. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN TU). Available at: http://clinicaltrials.gov/show/ NCT01760005 (accessed 28 October 2013).
30. NCT01723826. A Long-Term Safety Extension Study of Studies ABE4869 g And ABE4955 g in Patients With Mild To Moderate Alzheimer's Disease Treated With Crenezumab. Available at: http://clinicaltrials.gov/show/NCT01723826 (accessed 28 October 2013).
31. NCT00818662. A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer's Disease-A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/NCT00818662 (accessed 28 October 2013).
32. NCT01097096. Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients. Available at: http://clinicaltrials.gov/show/NCT01097096 (accessed 28 October 2013).
33. NCT00004845. A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study). Available at: http://clinicaltrials.gov/show/NCT00004845 (accessed 28 October 2013).
34. NCT00046358. The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease. http://clinicaltrials.gov/show/NCT000046358 (accessed 28 October 2013).
35. NCT00486044. Evaluating Simvastatin's Potential Role in Therapy (ESPRIT). Available at: http://clinicaltrials.gov/show/NCT00486044 (accessed 28 October 2013).
36. Dunkel P, Chai CL, Sperlagh B, Huleatt PB, Matyus P,. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs, 2012; 21: 1267-1308.
37. May PC, Dean RA, Lowe SL, et al,. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci, 2011; 31: 16507-16516.
38. Nordqvist J, (2012) Merck's Alzheimer's Disease BACE Inhibitor Drug MK-8931 Begins Phase II/III Clinical Trial. Available at: http://www. medicalnewstoday.com/articles/253517.php (accessed 28 October 2013).
39. Anonymous. (2013) Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer's Disease. Available at: http://www. businesswire.com/news/home/20130313005378/en/Merck-Luminex-Corporation-Enter- Agreement-Develop-Companion (accessed 28 October 2013).
40. NCT01739647. A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects. Available at: http://clinicaltrials.gov/ct2/show/NCT01739647. (accessed 28 October 2013).
41. Anonymous. (2013) http://www.ttpharma.com/TherapeuticAreas/ AlzheimersDisease/HPP854/tabid/125/Default.aspx. (accessed 28 October 2013).
42. PhRMA. (2012) Medicines in development: Alzheimer's disease. Available at: http://phrma.org/sites/default/files/pdf/alzheimers2012.pdf. (accessed 28 October 2013).
43. Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA,. Identification of BACE2 as an avid ss-amyloid-degrading protease. Mol Neurodegener, 2012; 7: 46.
44. Coric V, van Dyck CH, Salloway S, et al,. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol, 2012; 69: 1430-1440.
45. Henley DB, May PC, Dean RA, Siemers ER,. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother, 2009; 10: 1657-1664.
46. Anonymous. (2010) Press release: Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials. Available at: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID= 499794 (accessed 28 October 2013).
47. McKee S, (2010) Lilly Hit by Spectacular Failure of Phase III Alzheimer's Candidate. PharmaTimes Online. Available at: http://www.pharmatimes.com/ article/10-08-18/Lilly-hit-by-spectacular-failure-of-Phase-III-Alzheimer-s- candidate.aspx (accessed 28 October 2013).
48. Anonymous. (2012) 2012: A Pivotal Year for Alzheimer's Disease Drug Development. Available at: http://www.minyanville.com/sectors/biotech-pharma/ articles/alzheimers-disease-alzheimers-alzheimer-disease-eli/4/10/2012/id/40336 (accessed 28 October 2013).
49. La Porte SL, Bollini SS, Lanz TA, et al,. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol, 2012; 421: 525-536.
50. n T. (2011) Pfizer Halts Development of Aβ Antibody. Available at: http://www.alzforum.org/new/detail.asp?id=2950. (accessed 28 October 2013).
51. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J,. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA, 2004; 101 (Suppl 2): 14657-14662.
52. NCT01117818. Clinical- and Immunological Activity, Safety and Tolerability of Different Doses/Formulations of AFFITOPE AD02 in Early Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/NCT01117818 (accessed 28 October 2013).
53. NCT00464334. A Study of V950 in People With Alzheimer Disease (V950-001 AM7). Available at: http://clinicaltrials.gov/show/NCT00464334 (accessed 28 October 2013).
54. Aisen PS, Schafer KA, Grundman M, et al,. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 2003; 289: 2819-2826.
55. 1492374. Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/NCT01492374 (accessed 28 October 2013).
56. Alzheimer Research Forum. Drugs In Clinical Trials. Available at: http://www.alzforum.org/dis/tre/drc/ (accessed 28 October 2013).
57. Alzheimer Research Forum. Will Tau Drug Show Its True Colors in Phase 3 Trials? Available at: http://www.alzforum.org/new/detail.asp?id=3283 (accessed 28 October 2013).
58. Eisai. Eisai Announces the Start of the First Clinical Study of ban2401, a Novel Monoclonal Antibody Targeting the Neurotoxic Protofibrils Believed to Cause Alzheimer's Disease. 2010. Available at: http://www.eisai.com/news/ news201044.html (accessed 28 October 2013).
59. GSK. (2013) Modulation of Beta-Amyloid Levels in CSF and Plasma by GSK933776 in Patients with Mild Alzheimer's Disease or Mild Cognitive Impairment. Available at: http://www.gsk-clinicalstudyregister.com/result-comp- list.jsp?compound=GSK933776&studyType=All&phase=All&population= All&marketing=All accessed 28 October 2013).
60. NCT00965588. http://clinicaltrials.gov/show/NCT00965588. Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease. Available at: http://clinicaltrials.gov/show/ NCT00965588 (accessed 28 October 2013).
61. Steenhuysen J, (2013) After Failed Trials, J&J Pivots to Early-Stage Alzheimer's. Available at: http://www.reuters.com/article/2013/02/13/us- alzheimers-johnsonjohnson-idUSBRE91C0SX20130213 (accessed 28 October 2013).
62. Kolata G, (2012) Three Drugs to Be Tested to Stave Off Alzheimer's. Available at: http://www.nytimes.com/2012/10/11/health/alzheimers-prevention- studies-to-test-three-drugs.html (accessed 28 October 2013).
63. NIA(NIH). Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU). Available at: http://www.nia.nih.gov/alzheimers/ clinical-trials/dominantly-inherited-alzheimer-network-trial-opportunity- prevent-dementia (accessed 28 October 2013).
64. Bookheimer SY, Strojwas MH, Cohen MS, et al,. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med, 2000; 343: 450-456.
65. Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H,. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin North Am, 2013; 97: 399-424.
66. Sperling RA, Aisen PS, Beckett LA, et al,. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011; 7: 280-292.
67. Strobel G, Zakaib D, (2013) Solanezumab Selected for Alzheimer's A4 Prevention Trial. Available at: http://www.alzforum.org/new/detail.asp?id=3379 (accessed 28 October 2013).
68. Anonymous. (2012) Press release: Lilly Provides Update on Next Steps for Solanezumab. Available at: http://newsroom.lilly.com/releasedetail.cfm? ReleaseID=726309 (accessed 28 October 2013).
69. Wasson AS, (2013) Early-Stage Alzheimer's Disease Drug Development Draft Guidance Issued by FDA. Available at: http://www.fdalawyersblog.com/2013/02/ early-stage-alzheimers-disease.html (accessed 28 October 2013).
70. FDA. (2013) Guidance for Industry-Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf (accessed 28 October 2013).
71. Patel L, Grossberg GT,. Combination therapy for Alzheimer's disease. Drugs Aging, 2011; 28: 539-546.
72. Sarazin M, de SL, Lehericy S, Dubois B, Clinical and research diagnostic criteria for Alzheimer's disease. Neuroimaging Clin N Am, 2012; 22: 23-32,viii.
73. Noble JM, Scarmeas N,. Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment. Int Rev Neurobiol, 2009; 84: 133-149.
74. Rollin-Sillaire A, Bombois S, Deramecourt V, et al,. Contribution of single photon emission computed tomography to the differential diagnosis of dementia in a memory clinic. J Alzheimer's Dis, 2012; 30: 833-845.
75. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F,. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol, 2012; 69: 824-831.
76. Seppälä TT, Nerg O, Koivisto AM, et al,. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology, 2012; 78: 1568-1575.
77. Nelissen N, Van Laere K, Thurfjell L, et al,. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med, 2009; 50: 1251-1259.
78. Anonymous. (2013) Press Release: Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE Inhibitor Clinical Development Program. Available at: http://www.merck.com/licensing/our- partnership/GE-healthcare-partnership.html (accessed 28 October 2013).
79. 18F]Flutemetamol Data Presented at 6th Annual Human Amyloid Imaging Conference. Available at: http://www.businesswire.com/news/home/20120117006572/en/GE-Healthcare-18F- Flutemetamol-Data-Presented-6th (accessed 28 October 2013).
80. Anonymous. (2013) GE Healthcare Announces Data from [18F]flutemetamol Phase III Studies on Alzheimer's. Available at: http://www.news-medical.net/ news/20120911/GE-Healthcare-announces-data-from-18Fflutemetamol-phase-III- studies-on-Alzheimers.aspx (accessed 28 October 2013).